A Phase 3 interventional study of Pemetrexed and Paclitaxel in Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell and Non-small-cell Lung Carcinoma, sponsored by Regeneron Pharmaceuticals. Completed at 192 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 5 in phase 3, and was the 1st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Georgetown University · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
UNICANCER · Sites in France
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Austria, Estonia, France and 6 more countries
Ages 18+
Maia Biotechnology · Sites in Poland, Romania, Taiwan and 1 more country
Ages 18+
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 6
First in 2017; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 712 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 61 across the 29 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 29 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals: 2 open now, 11 under way, 2 of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 3, and was the 2nd registered.
Regeneron Pharmaceuticals’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2008.
3 of the studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06908304Phase 3Maia BiotechnologyA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | 2027-07-31 |
| NCT06088771Icahn School of Medicine at Mount SinaiNeoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | 2026-12-01 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Regeneron Pharmaceuticals’s 21 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are:
The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies
There is option to join genomics sub-study.
Key Inclusion Criteria:
A patient must meet the following criteria to be eligible for inclusion in the study:
Key Exclusion Criteria:
A patient who meets any of the following criteria will be excluded from the study:
Note: Other protocol defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard-of-care chemotherapy will administered from these options: Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance
Drug: Pemetrexed · Drug: Paclitaxel · Drug: Gemcitabine · Drug: Cisplatin · Drug: Carboplatin
cemiplimab regimen as monotherapy as per study protocol
Drug: cemiplimab
Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
Administered with either Pemetrexed, Paclitaxel or gemcitabine.
Administered with either Pemetrexed, Paclitaxel or gemcitabine.
Patients will be administered cemiplimab as per protocol.
Also known as: REGN2810, Libtayo
Overall Survival (OS)
OS was defined as the time from randomization to the date of death due to any cause.
Time frame: Up to 94 months
Progression-free Survival (PFS) Per Blinded IRC
PFS as assessed by blinded IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.
Time frame: Up to 94 months
Objective Response Rate (ORR) Per IRC
ORR was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by IRC per RECIST 1.1.
Time frame: Up to 73.5 months
Best Overall Response (BOR) Per IRC
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
Time frame: Up to 73.5 months
Duration of Response (DoR) Per IRC
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD (per RECIST 1.1) or death due to any cause, whichever occurred earlier.
Time frame: Up to 73.5 months
Change From Baseline in Global Health Status/Quality of Life (QoL) Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (physical, role, cognitive, emotional, social), 9 symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items: "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" Each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a score ranging from 0 to 100; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39
Change From Baseline in Coughing Scores as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)
EORTC QLQ-LC13 is a 13-item questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia). Reported here are the EORTC lung cancer coughing scores only. Scores were calculated and transformed to a range from 0 to 100, with a higher score representing a higher level of symptoms/problems and a negative change from baseline value indicating reduction (i.e. improvement) in symptoms.
Time frame: Baseline, Day 1 of 21-Day Cycles 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to 94 months
Number of Participants With Serious TEAEs
Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
Time frame: Up to 94 months
Number of Deaths During the On-Treatment Period
The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
Time frame: Up to approximately 28 months
Number of Participants With Laboratory Abnormalities
Reported here is the number of participants with at least one laboratory abnormality of any grade in measurements for hematology, electrolytes, liver function, chemistry, and coagulation.
Time frame: Up to approximately 28 months
Trough Concentration (Ctrough) of Cemiplimab in Serum
Time frame: Up to 73.5 months
Maximum Plasma Concentration (Cmax) of Cemiplimab in Serum
Time frame: Up to 73.5 months
Number of Participants With Anti-Cemiplimab Antibodies (ADA)
The ADA status of each participant was classified as one of the following: * Pre-existing - If the baseline sample is positive and all post baseline ADA titers are reported as less than 9-fold the baseline titer value * Negative - If all samples are found to be negative in the ADA assay * Treatment-emergent response
Time frame: Up to 73.5 months
Number of Participants With Neutralizing Antibodies (NAb)
The NAb status of each participant was categorized as follows: * Negative - Samples that tested negative in the ADA assay, or samples positive in the ADA assay but tested negative in the NAb assay * Positive
Time frame: Up to 73.5 months
| Milestone | Cemiplimab | Chemotherapy |
|---|---|---|
| Started | 357 | 355 |
| Randomized and treated | 356 | 343 |
| Completed treatment | 73 | 161 |
| Completed | 75 | 35 |
| Not completed | 282 | 320 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 157 | 184 |
| Withdrew: Lost to follow-up | 10 | 6 |
| Withdrew: Subject decision | 33 | 24 |
| Withdrew: Sponsor decision | 1 | 1 |
| Withdrew: Physician decision | 3 | 6 |
| Withdrew: Disease progression | 35 | 35 |
| Withdrew: Withdrawal by subject | 39 | 56 |
| Withdrew: Other than specified | 3 | 8 |
OS was defined as the time from randomization to the date of death due to any cause.
| months | Cemiplimab | Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 23.4 (19.4 to 27.6) | 13.7 (11.2 to 16.2) |
PFS as assessed by blinded IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.
| months | Cemiplimab | Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) Per Blinded IRC | 6.3 (4.6 to 8.3) | 5.3 (4.3 to 6.0) |
ORR was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by IRC per RECIST 1.1.
| percentage of participants | Cemiplimab | Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) Per IRC | 42.3 (37.1 to 47.6) | 21.4 (17.3 to 26.0) |
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
| Participants | Cemiplimab | Chemotherapy |
|---|---|---|
| Complete Response (CR) | 30 | 4 |
| Partial Response (PR) | 121 | 72 |
| Stable Disease (SD) | 90 | 175 |
| Non-CR/Non-PD | 2 | 4 |
| Progressive Disease (PD) | 76 | 56 |
| Not Evaluable (NE) | 38 | 44 |
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD (per RECIST 1.1) or death due to any cause, whichever occurred earlier.
| months | Cemiplimab | Chemotherapy |
|---|---|---|
| Duration of Response (DoR) Per IRC | 24.1 (18.6 to 35.2) | 5.9 (4.3 to 6.3) |
The EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall QoL in cancer participants. It consists of 15 domains: 1 Global Health Status (GHS)/QoL scale, 5 functional scales (physical, role, cognitive, emotional, social), 9 symptom scales/items (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Reported here are the EORTC QLQ-C30 GHS/QoL scores only. GHS/QoL is derived from two items: "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" Each scored from 1 (very poor) to 7 (excellent). The average of these two items is linearly transformed to a score ranging from 0 to 100; higher scores indicate better overall quality of life, and a positive change from baseline reflects improvement.
| score on a scale | Cemiplimab | Chemotherapy |
|---|---|---|
| Cycle 2, Day 1 (C2D1) | 4.92 ± 20.455 | 0.45 ± 19.291 |
| C3D1 | 7.23 ± 21.928 | 1.25 ± 21.019 |
| C4D1 | 8.13 ± 21.925 | 2.43 ± 21.795 |
| C5D1 | 8.27 ± 24.422 | 1.88 ± 21.803 |
| C6D1 | 9.64 ± 22.910 | 3.00 ± 20.909 |
| C9D1 | 10.19 ± 23.359 | 2.55 ± 20.142 |
| C12D1 | 11.11 ± 23.077 | -4.17 ± 19.543 |
| C15D1 | 10.88 ± 24.705 | 5.36 ± 19228 |
| C18D1 | 10.10 ± 26.792 | -3.03 ± 22.753 |
| C21D1 | 13.42 ± 25.060 | -1.19 ± 11.210 |
| C24D1 | 10.76 ± 22.676 | 1.19 ± 12.199 |
| C27D1 | 12.50 ± 24.225 | -3.33 ± 12.638 |
| C30D1 | 11.74 ± 24.358 | -4.17 ± 10.758 |
| C33D1 | 9.62 ± 26.355 | 0.00 ± 11.785 |
| C36D1 | 11.69 ± 24.928 | 4.17 ± 5.893 |
| C39D1 | — | 8.33 |
EORTC QLQ-LC13 is a 13-item questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia). Reported here are the EORTC lung cancer coughing scores only. Scores were calculated and transformed to a range from 0 to 100, with a higher score representing a higher level of symptoms/problems and a negative change from baseline value indicating reduction (i.e. improvement) in symptoms.
| score on a scale | Cemiplimab | Chemotherapy |
|---|---|---|
| Cycle 2, Day 1 (C2D1) | -4.12 ± 25.777 | -4.32 ± 26.406 |
| C3D1 | -8.60 ± 29.824 | -8.56 ± 29.059 |
| C4D1 | -11.19 ± 28.598 | -11.41 ± 30.181 |
| C5D1 | -12.41 ± 31.065 | -9.86 ± 31.752 |
| C6D1 | -13.33 ± 30.251 | -11.11 ± 28.142 |
| C9D1 | -13.12 ± 29.601 | -12.24 ± 31.691 |
| C12D1 | -13.22 ± 28.179 | -5.56 ± 30.429 |
| C15D1 | -15.65 ± 27.116 | -19.05 ± 31.254 |
| C18D1 | -16.16 ± 27.777 | -15.15 ± 27.340 |
| C21D1 | -17.70 ± 28.546 | -19.05 ± 26.227 |
| C24D1 | -18.30 ± 28.773 | -28.57 ± 23.002 |
| C27D1 | -17.75 ± 34.041 | -26.67 ± 27.889 |
| C30D1 | -18.94 ± 31.882 | -16.67 ± 33.333 |
| C33D1 | -18.38 ± 30.222 | -8.33 ± 41.944 |
| C36D1 | -22.22 ± 28.527 | -16.67 ± 23.570 |
| C39D1 | — | 0.00 |
TEAEs were AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Cemiplimab | Chemotherapy |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 330 | 329 |
Serious TEAEs were defined as medically significant but not immediately life-threatening AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occurred during the post-treatment period but prior to start of another anti-cancer systemic therapy.
| Participants | Cemiplimab | Chemotherapy |
|---|---|---|
| Number of Participants With Serious TEAEs | 127 | 101 |
The on-treatment period was defined as the day from the first dose of study drug to the day of the last dose of study drug plus 90 days or 1 day before participants receive their first dose of new anti-cancer systemic therapy, whichever is earlier.
| Participants | Cemiplimab | Chemotherapy |
|---|---|---|
| Number of Deaths During the On-Treatment Period | 87 | 80 |
Reported here is the number of participants with at least one laboratory abnormality of any grade in measurements for hematology, electrolytes, liver function, chemistry, and coagulation.
| Participants | Cemiplimab | Chemotherapy |
|---|---|---|
| Hematology | 230 | 301 |
| Electrolytes | 278 | 253 |
| Liver Function | 255 | 195 |
| Chemistry | 296 | 258 |
| Coagulation | 40 | 21 |
| milligrams per liter (mg/L) | Cemiplimab |
|---|---|
| Trough Concentration (Ctrough) of Cemiplimab in Serum | 59.7 ± 28.4 |
| mg/L | Cemiplimab |
|---|---|
| Maximum Plasma Concentration (Cmax) of Cemiplimab in Serum | 184 ± 101 |
The ADA status of each participant was classified as one of the following: * Pre-existing - If the baseline sample is positive and all post baseline ADA titers are reported as less than 9-fold the baseline titer value * Negative - If all samples are found to be negative in the ADA assay * Treatment-emergent response
| Participants | Cemiplimab |
|---|---|
| Negative | 241 |
| Pre-existing | 9 |
| Treatment-emergent Response | 5 |
The NAb status of each participant was categorized as follows: * Negative - Samples that tested negative in the ADA assay, or samples positive in the ADA assay but tested negative in the NAb assay * Positive
| Participants | Cemiplimab |
|---|---|
| NAb Negative | 255 |
| NAb Positive | 0 |
Collected over From signing of first informed consent up to 94 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cemiplimab | 178/356 (50%) | 131/356 (36.8%) | 287/356 (80.6%) |
| Extended Treatment: Cemiplimab + Chemotherapy | 60/85 (70.6%) | 23/85 (27.1%) | 70/85 (82.4%) |
| Chemotherapy | 116/343 (33.8%) | 103/343 (30%) | 319/343 (93%) |
| Crossover: Chemotherapy to Cemiplimab | 141/191 (73.8%) | 57/191 (29.8%) | 141/191 (73.8%) |
| Event | Cemiplimab | Extended Treatment: Cemiplimab + Chemotherapy | Chemotherapy | Crossover: Chemotherapy to Cemiplimab |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 22/356 | 0/85 | 20/343 | 9/191 |
| AnaemiaBlood and lymphatic system disorders | 6/356 | 3/85 | 16/343 | 6/191 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 8/356 | 1/85 | 0/343 | 6/191 |
| DeathGeneral disorders | 6/356 | 2/85 | 2/343 | 4/191 |
| DiarrhoeaGastrointestinal disorders | 1/356 | 2/85 | 1/343 | 0/191 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/356 | 0/85 | 8/343 | 0/191 |
| Urinary tract infectionInfections and infestations | 1/356 | 1/85 | 3/343 | 4/191 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/356 | 0/85 | 7/343 | 0/191 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/356 | 1/85 | 6/343 | 2/191 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/356 | 1/85 | 2/343 | 0/191 |
| Event | Cemiplimab | Extended Treatment: Cemiplimab + Chemotherapy | Chemotherapy | Crossover: Chemotherapy to Cemiplimab |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 70/356 | 27/85 | 175/343 | 39/191 |
| NauseaGastrointestinal disorders | 29/356 | 16/85 | 99/343 | 10/191 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/356 | 19/85 | 86/343 | 3/191 |
| Decreased appetiteMetabolism and nutrition disorders | 49/356 | 7/85 | 66/343 | 19/191 |
| FatigueGeneral disorders | 48/356 | 7/85 | 65/343 | 19/191 |
| DiarrhoeaGastrointestinal disorders | 33/356 | 16/85 | 32/343 | 9/191 |
| NeutropeniaBlood and lymphatic system disorders | 10/356 | 12/85 | 62/343 | 5/191 |
| ConstipationGastrointestinal disorders | 29/356 | 6/85 | 58/343 | 11/191 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/356 | 3/85 | 52/343 | 6/191 |
| VomitingGastrointestinal disorders | 18/356 | 7/85 | 49/343 | 6/191 |
The full analysis set (FAS) included all randomized participants.
| Age, Continuous(years) | Cemiplimab | Chemotherapy | Total |
|---|---|---|---|
| Mean | 63.0 ± 8.18 | 63.3 ± 8.55 | 63.1 ± 8.36 |
| Sex: Female, Male(Participants) | Cemiplimab | Chemotherapy | Total |
|---|---|---|---|
| Female | 44 | 61 | 105 |
| Male | 313 | 294 | 607 |
| Ethnicity (NIH/OMB)(Participants) | Cemiplimab | Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 36 | 26 | 62 |
| Not Hispanic or Latino | 321 | 328 | 649 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Cemiplimab | Chemotherapy | Total |
|---|---|---|---|
| White | 309 | 306 | 615 |
| Black or African American | 1 | 3 | 4 |
| Asian | 39 | 38 | 77 |
| American Indian or Alaska Native | 6 | 8 | 14 |
| Other | 2 | 0 | 2 |
Showing the first 100 of 192 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from May 2017 to primary completion in Apr 2025, 94 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 94 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab
Carcinoma, Non-Small-Cell Lung →